The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL HL Update 2021 | Relapsed & refractory classic Hodgkin lymphoma
Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses second-line approaches in Hodgkin lymphoma (HL) including the use of autologous stem cell transplantation which is associated with an improvement in progression-free survival. Dr Moskowtiz highlights chemotherapeutic approaches as bridges to transplant, as well as regimens including brentuximab vedotin alone and in combination with nivolumab. Combination pembrolizumab, gemcitabine, vinorelbine, and doxorubicin as second-line therapy is also discussed by Dr Moskowitz as an alternative to brentuximab vedotin in the second-line, and Dr Moskowitz highlights how this regimen has shown favorable responses in patients with Hodgkin lymphoma, with the majority of patients undergoing transplant. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
